Skip to main content

Company

Emyria Ltd

ASX:EMD

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development.

28 stories

Pharma & Biotech

Emyria on track for first Victorian Empax clinic launch in Q2 2026

By Proactive 24/03

Pharma & Biotech

Emyria delivers more than $2 million in clinical billings in the past half-year

By Proactive 29/02/2024

Pharma & Biotech

Emyria kicks off year with $2.5 million R&D incentive on the heels of Authorised Prescriber status

By Proactive 15/01/2024

Pharma & Biotech

Emyria gains authorised provider status for MDMA from TGA for post-traumatic stress disorder

By Proactive 10/01/2024

Pharma & Biotech

Emyria welcomes eminent healthcare leader to enhance mental health initiatives

By Proactive 21/11/2023

Pharma & Biotech

Emyria restructures board amid cost efficiency commitment

By Proactive 13/11/2023

Pharma & Biotech

Emyria secures ethics endorsement for MDMA Authorised Prescriber application, clearing way for TGA decision

By Proactive 30/10/2023

Pharma & Biotech

Emyria given green light to import MDMA for therapeutic trials in Australia

By Proactive 19/10/2023

Pharma & Biotech

Emyria completes first approved MDMA-assisted therapy dosing

By Proactive 09/10/2023

Pharma & Biotech

Emyria completes entitlement offer, raises $1.18m ahead of MDMA-assisted therapy trial

By Proactive 05/10/2023

Pharma & Biotech

Emyria secures local MDMA paving way for PTSD trial dosing

By Proactive 21/09/2023

Pharma & Biotech

Emyria completes Pax Centre acquisition to boost mental health care and drug development

By Proactive 13/09/2023

Pharma & Biotech

Emyria raises $2 million in placement; launches $3.1 million entitlement offer

By Proactive 04/09/2023

Pharma & Biotech

Emyria appoints clinical transformation and digital health expert to board

By Proactive 21/08/2023

Pharma & Biotech

Emyria launches ketamine-assisted therapy program; taps expert Dr Ben Sessa to lead

By Proactive 08/08/2023

Pharma & Biotech

Emyria recruits first patient in Phase 2B trial of MDMA for post-traumatic stress disorder

By Proactive 10/07/2023

Pharma & Biotech

Emyria pursues a unique opportunity in psychedelic-assisted therapy

By Proactive 06/07/2023

Pharma & Biotech

Emyria set to snap up leading psychological trauma care service, the Pax Centre

By Proactive 03/07/2023

Pharma & Biotech

Cannabis and psychedelic regulation in Australia

By Proactive 27/06/2023

Pharma & Biotech

The smart money in medicine: cannabis and psychedelics come of age

By Proactive 13/06/2023

Pharma & Biotech

Emyria gains ethics approval for landmark MDMA-assisted PTSD therapy trial

By Proactive 08/06/2023

Pharma & Biotech

Emyria completes $2.5M placement to advance MDMA-assisted therapy

By Proactive 01/05/2023

Pharma & Biotech

Emyria expands CBD pipeline with launch of highest potency Ultra-Pure CBD capsule

By Proactive 24/04/2023

Pharma & Biotech

Emyria extends PAX partnership to develop psilocybin-assisted therapy care model

By Proactive 18/04/2023

Pharma & Biotech

Emyria and pharma company Aspen Australia ink agreement to license and commercialise EMD-RX5 as OTC anxiety medication

By Proactive 04/04/2023

Pharma & Biotech

Emyria experiences high patient demand as it enrols for Phase 3 trial of OTC treatment for stress and anxiety

By Proactive 23/03/2023

Pharma & Biotech

Emyria and UWA expand MDMA analogue library to target neurological and mental health conditions

By Proactive 20/03/2023

Pharma & Biotech

Emyria collaborates with psychiatrist-led clinical service in MDMA-assisted therapy for PTSD

By Proactive 07/03/2023